Scaling MSC Therapies: Overcoming MSC Manufacturing Risks And Barriers

Transitioning mesenchymal stem cell (MSC) therapies from research to commercial manufacturing introduces a unique set of operational and biological hurdles. This seminar features insights from bioprocessing experts on how to manage donor variability and limited passage windows while meeting the high cell volumes required for modern regenerative medicine. The discussion centers on moving beyond manual T-flask methods toward automated, closed-system platforms that minimize contamination risk and enhance reproducibility.

By evaluating key factors such as media efficiency, facility footprints, and regulatory compliance, developers can select the most appropriate architecture—whether multi-layer vessels, high-density stacks, or fixed-bed bioreactors. The session also addresses critical manufacturing strategies, including metabolite monitoring to optimize media usage and the implementation of aseptic connections to ensure GMP readiness. Understanding these logistical considerations is essential for reducing redevelopment work and accelerating the journey toward clinical delivery. Discover practical approaches for standardizing your production workflow to achieve consistent, high-quality results at scale.